Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former US FDA Chief Counsels Offer Advice For Navigating Thorny First Amendment Conundrum

Executive Summary

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends bully pulpit approach to get attention of industry; panel of former chief counsels stresses that agency cannot continue to ignore First Amendment issues.

You may also be interested in...



Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says

Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

Xtampza ER Warnings Can't Be Hidden Behind Table And Chairs, US FDA Tells Collegium

OPDP's first enforcement letter of 2018 is notable because it comes much earlier than 2017's first, cites an opioid, and signals that the US FDA is monitoring medical meetings. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel